Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Tesla delivers record Q3 vehicles, but misses earnings expectations as costs rise, signaling the company's shift towards 'real-world AI' and energy initiatives.
Moderna halts development of its experimental CMV vaccine after Phase III trial fails to meet primary endpoint, leaving the field without an approved congenital CMV vaccine.
Tesla delivers record Q3 vehicles, but misses earnings expectations as costs rise, signaling the company's shift towards 'real-world AI' and energy initiatives.